Prometheus Biosciences, Inc.

NasdaqGS:RXDX Lagerbericht

Marktkapitalisierung: US$9.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Prometheus Biosciences Management

Management Kriterienprüfungen 1/4

Prometheus Biosciences' CEO is Mark McKenna, appointed in Sep 2019, he has a tenure of 3.75 years. His total yearly compensation is $19.94M , comprised of 3% salary and 97% bonuses, including company stock and options. He directly owns 0.29% of the company’s shares, worth $28.17M. The average tenure of the management team and the board of directors is 2.5 years and 2.3 years respectively.

Wichtige Informationen

Mark McKenna

Geschäftsführender

US$19.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts3.0%
Amtszeit als Geschäftsführer3.8yrs
Eigentum des Geschäftsführers0.3%
Durchschnittliche Amtszeit des Managements2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder2.3yrs

Jüngste Management Updates

Recent updates

We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

May 17
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

Dec 03
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Aug 19
We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M

Aug 11

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

May 04
We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Dec 08

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Nov 16
Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Prometheus Biosciences: Precision Medicine For IBD

Sep 22

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Mark McKenna im Vergleich zu den Einnahmen von Prometheus Biosciences verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2023n/an/a

-US$151m

Dec 31 2022US$20mUS$592k

-US$142m

Sep 30 2022n/an/a

-US$133m

Jun 30 2022n/an/a

-US$123m

Mar 31 2022n/an/a

-US$108m

Dec 31 2021US$12mUS$566k

-US$90m

Sep 30 2021n/an/a

-US$69m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$3mUS$500k

-US$31m

Dec 31 2019US$976kUS$157k

-US$17m

Vergütung im Vergleich zum Markt: Mark's total compensation ($USD19.94M) is above average for companies of similar size in the US market ($USD8.17M).

Entschädigung vs. Einkommen: Mark's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Mark McKenna (43 yo)

3.8yrs

Amtszeit

US$19,936,088

Vergütung

Mr. Mark C. Mckenna serves as President, Chief Executive Officer, Chairman of the Board at Prometheus Biosciences, Inc. since August 2021. He serves as Director of Rebalance Health, Inc. He serves as Execu...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Mark McKenna
President3.8yrsUS$19.94m0.29%
$ 28.2m
Keith Marshall
Chief Financial Officer2.8yrsUS$7.12m0.18%
$ 17.6m
Mark Stenhouse
Chief Operating Officer2.3yrsUS$6.16m0.035%
$ 3.4m
Olivier Laurent
Chief Scientific Officer & Head of R&D1.5yrskeine Datenkeine Daten
Noel Kurdi
Vice President of Investor Relations & Communicationsno datakeine Datenkeine Daten
Timothy Andrews
General Counsel & Secretary2.6yrskeine Datenkeine Daten
Nori Ebersole
Chief People Officer2.2yrskeine Datenkeine Daten
Allison Luo
Chief Medical Officer4.8yrsUS$4.24m0%
$ 0
Thierry Dervieux
Chief Development Officer of Diagnostics & Medical Laboratory Director3.5yrskeine Datenkeine Daten
Chris Doughty
Chief Business Officer2.4yrskeine Datenkeine Daten
Evan McClure
Chief of Staff & VP of Business Operations2.4yrskeine Datenkeine Daten
Vika Brough
Senior Vice President of Financeno datakeine Datenkeine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: RXDX's management team is considered experienced (2.5 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Mark McKenna
President3.8yrsUS$19.94m0.29%
$ 28.2m
Fred Hassan
Independent Director2.1yrsUS$441.91k0%
$ 0
Joseph Papa
Lead Independent Director2.8yrsUS$463.28k0.031%
$ 3.0m
Mary Szela
Independent Director2.3yrsUS$442.29k0%
$ 0
Judith Swain
Independent Director2.3yrsUS$429.79k0%
$ 0
Helen Adams
Independent Director2.3yrsUS$444.04k0.0010%
$ 100.4k
Bruce Sands
Chairman of Scientific Advisory Board1.1yrskeine Datenkeine Daten
Stephan Targan
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Martin Hendrix
Independent Director2.7yrsUS$439.79k0%
$ 0
James Laur
Director3.2yrsUS$424.79k0%
$ 0
Dermot McGovern
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Donna Griebel
Member of Scientific Advisory Boardno datakeine Datenkeine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: RXDX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.